Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMN6Q4E)

Drug Name

Polyporic acid Drug Info

Synonyms

Polyporic acid; Polyporin; Orygameic acid; 548-59-4; 2,5-Dihydroxy-3,6-diphenyl-p-benzoquinone; NSC 44175; S 1148; NSC44175; BRN 2057889; 2,5-Dihydroxy-3,6-diphenyl-2,5-cyclohexadiene-1,4-dione; 2,5-Cyclohexadiene-1,4-dione, 2,5-dihydroxy-3,6-diphenyl-; p-BENZOQUINONE, 2,5-DIHYDROXY-3,6-DIPHENYL-; 2,5-Dihydroxy-3,6-diphenylbenzo-1,4-quinone; AC1L1WIT; 4-08-00-03298 (Beilstein Handbook Reference); SCHEMBL2445444; CTK1H0626; DTXSID50203281; MolPort-003-979-960; HZKFHDXTSAYOSN-UHFFFAOYSA-N

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 11056
ChEBI ID: CHEBI:144197
CAS Number: CAS 548-59-4
TTD Drug ID: DMN6Q4E

Molecule-Related Drug Atlas

Molecule Type:

DTT

DOT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Artemisinin	DMOY7W3	Malaria	1F40-1F45	Approved	[2]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[3]
Teriflunomide	DMQ2FKJ	Hyperlipidaemia	5C80	Approved	[4]
Atovaquone	DMY4UMW	Fungal infection	1F29-1F2F	Approved	[5]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[1]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[6]
B-Octylglucoside	DMMO75G	Discovery agent	N.A.	Investigative	[6]
Orotate	DMMB29S	Discovery agent	N.A.	Investigative	[7]
Lauryl Dimethylamine-N-Oxide	DM3W2OE	Discovery agent	N.A.	Investigative	[6]
1,4-Naphthoquinone	DMTCMH7	Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Dihydroorotate dehydrogenase (DHODH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[8]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[9]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[10]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[11]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[12]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[13]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[14]
Atovaquone	DMY4UMW	Fungal infection	1F29-1F2F	Approved	[1]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[15]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)	TT3PQ2Y	PYRD_PLAF7	Inhibitor	[1]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Dihydroorotate dehydrogenase (DHODH)	OTAKFN78	PYRD_HUMAN	Gene/Protein Processing	[1]

------------------------------------------------------------------------------------

References

1	Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76.
2	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
3	Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases. Eur J Biochem. 1999 Dec;266(3):1184-91.
4	Expression and characterization of E. coli-produced soluble, functional human dihydroorotate dehydrogenase: a potential target for immunosuppression. J Mol Microbiol Biotechnol. 1999 Aug;1(1):183-8.
5	Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci. 2004 Apr;13(4):1031-42.
6	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7	Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301.
8	Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
9	Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives. Biochem Pharmacol. 1998 Nov 1;56(9):1259-64. doi: 10.1016/s0006-2952(98)00145-2.
10	Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
11	Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
12	Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
13	Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
14	17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
15	Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.